Recombinant Human CBR1 protein

中文名： 羰基还原酶1(CBR1)重组蛋白
别名： CBR1；CBR；CRN；SDR21C1；Carbonyl reductase [NADPH] 1

货号: PA1000-437DB

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	> 90 % SDS-PAGE.
种属	Human
靶点	CBR1
Uniprot No	P16152
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	2-277aa
氨基酸序列	SSGIHVALVTGGNKGIGLAIVRDLCRLFSGDVVLTARDVTRGQAAVQQLQAEGLSPRFHQLDIDDLQSIRALRDFLRKEYGGLDVLVNNAGIAFKVADPTPFHIQAEVTMKTNFFGTRDVCTELLPLIKPQGRVVNVSSIMSVRALKSCSPELQQKFRSETITEEELVGLMNKFVEDTKKGVHQKEGWPSSAYGVTKIGVTVLSRIHARKLSEQRKGDKILLNACCPGWVRTDMAGPKATKSPEEGAETPVYLALLPPDAEGPHGQFVSEKRVEQW
预测分子量	32.2kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于CBR1重组蛋白的模拟参考文献示例(非真实文献，仅供格式参考)：

---

1. **《Cloning and functional characterization of human carbonyl reductase 1 in E. coli》**

- 作者：Watanabe, K. et al.

- 摘要：研究报道了人源CBR1基因在大肠杆菌中的重组表达与纯化，分析了其酶活性对多种底物(如异源生物质代谢物)的催化效率，并探讨了pH和温度对其功能的影响。

2. **《Structural insights into the substrate specificity of recombinant CBR1 through crystallography》**

- 作者：Skarydova, L. & Wsol, V.

- 摘要：通过X射线晶体学解析了重组CBR1蛋白的三维结构，揭示了其活性位点与NADPH/类固醇底物的结合模式，为设计选择性抑制剂提供了理论基础。

3. **《Role of recombinant CBR1 in chemoresistance: Implications for cancer therapy》**

- 作者：Hyatt, S.L. et al.

- 摘要：研究发现肿瘤细胞中过表达的重组CBR1可通过代谢化疗药物(如多柔比星)降低其细胞毒性，提示CBR1抑制剂可能逆转癌症耐药性。

4. **《Kinetic analysis of recombinant human CBR1 in anthracycline metabolism》**

- 作者：Bains, O.S. & Karkoura, R.

- 摘要：利用重组CBR1蛋白进行体外动力学实验，证明其在阿霉素等蒽环类药物代谢中的关键作用，并比较了不同基因多态性对酶活性的影响。

---

**注意**：以上文献为示例，实际研究中请通过PubMed、Web of Science等数据库检索真实文献。

背景信息

CBR1 (carbonyl reductase 1) is a NADPH-dependent short-chain dehydrogenase/reductase that plays a critical role in cellular detoxification and metabolism. It catalyzes the reduction of endogenous and exogenous carbonyl compounds, including prostaglandins, steroids, and quinone-based drugs, into their corresponding alcohols. This enzymatic activity positions CBR1 as a key player in xenobiotic metabolism, steroid homeostasis, and reactive aldehyde clearance, with implications in oxidative stress regulation and inflammatory responses.

The recombinant CBR1 protein, typically produced in *E. coli* or mammalian expression systems, retains the native enzyme's functional characteristics while offering standardized purity and activity for research. Its 30-kDa structure contains a conserved Rossmann-fold domain for cofactor binding and catalytic activity. Recombinant CBR1 has become essential for studying drug metabolism pathways, particularly in cancer therapeutics, as it mediates the bioactivation/detoxification of anthracyclines (e.g., doxorubicin) and other chemotherapeutic agents.

Recent studies highlight CBR1's dual role in cancer progression – acting as both a chemoprotective enzyme and a potential oncogenic driver in certain malignancies. Its overexpression has been linked to drug resistance in breast, lung, and ovarian cancers. Structural studies using recombinant protein have identified substrate-binding residues and potential inhibitor-binding sites, driving the development of CBR1-targeted adjuvants to enhance chemotherapy efficacy. Beyond oncology, recombinant CBR1 serves as a tool for investigating metabolic disorders, neurodegenerative diseases, and environmental toxicology, given its involvement in lipid peroxidation product metabolism and cellular redox balance. Current research focuses on its regulation by NRF2 and interactions with hypoxia-inducible factors, expanding its therapeutic relevance.